Shanghai, China, 13 June 2022 – MicroPort CardioFlow Medtech Corporation (“CardioFlow Medtech”) has been awarded a Silver A' Design Award for its VitaFlow Liberty™ Transcatheter Aortic Valve and Retrievable Delivery System (“VitaFlow Liberty™”). This is the second international design award received by VitaFlow Liberty™, following the 2022 German Red Dot Design Award.
The A' Design Awards is one of the largest design competitions in the world and is known for celebrating world-leading, pragmatic, forward-looking, experimental design. It is recognized as a major international design competition by the International Council of Design (Icograda) and the Bureau of European Design Associations (BEDA).
Tens of thousands of entries from around the world enter the awards each year, which are rigorously judged by a panel of internationally renowned experts from the academia members of the media, creative design professionals, and experienced entrepreneurs. More than 40,000 applications from over 180 countries were submitted in 2022 under 110 different design categories. The award is further international recognition for the innovative design of VitaFlow Liberty™ and for the CardioFlow brand more broadly.
VitaFlow Liberty™ is the first motorized retrievable transcatheter aortic valve system to be approved for marketing in China. It inherits the unique design of the original VitaFlow® Transcatheter Aortic Valve and Delivery System, featuring a hybrid density stent with double-layer skirts and a bovine pericardial leaflet. Its delivery system has been enhanced with a retrievable mechanism in addition to the motorized handle, which, along with the unique double-reinforced spiral structure, not only provides for fast, stable, and accurate release and retrieval, but also ensures superior flexibility and non-directionality. It is currently the only delivery system available in the Chinese market with a bendable distal end that can be bent 360 degrees.
VitaFlow Liberty™ is making steady international progress. Its first clinical implantation was in Argentina in August 2021, which was quickly followed by successful registeration in the same country in December 2021. As the only Chinese TAVI product undergoing clinical trials in Europe, VitaFlow Liberty™ has also formally applied for CE marking, which signifies yet another robust step onto the global stage. As its global clinical registration progresses, CardioFlow Medtech will continue to expand its overseas presence, promote its global reach, and provide a quality and inclusive product portfolio to doctors and patients worldwide.
About CardioFlow Medtech
MicroPort CardioFlow Medtech Corporation is a leading medical device company in China focusing on research, development and commercialization of innovative transcatheter and surgical solutions for structural heart diseases. On February 2021, The Company was listed on the Main Board of the Stock Exchange of Hong Kong Limited (Stock Code: 02160.HK), the Company’s self-developed first-generation Transcatheter Aortic Valve Implantation (TAVI) product, with its unique product design and outstanding clinical performance, has entered more than 300 hospitals across China and was successfully commercialized in Argentina. The Company’s second-generation TAVI product VitaFlow Liberty™ also the world’s only commercialized motorized retrievable system was approved by the NMPA in August 2021. In addition to the TAVI products, the company has also established a strategic R&D pipeline covering Transcatheter Mitral Valve (TMV) therapies, Transcatheter Tricuspid Valve (TTV) therapies, surgical valve products and surgical accessories via independent development and collaboration with global partners.